About Sai Sridhar Pharma Private Limited
Data last updated:
Sai Sridhar Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Nova Sud Pharmaceuticals Private Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 12 October 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2007PTC055902. Its GSTIN is 36AALCS7507A2ZF (Telangana). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹2.5 Lakh and a paid-up capital of ₹2.39 Lakh. It is led by directors including Phani Srinivas Ramella and Paidiwar Srinivas.
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No : 5 First Floor Opp : Idpl Company Balanagar, Hyderabad, Telangana, India – 500037.
As per the financials filed for FY 2025, the company reported a revenue of ₹349.28 Cr, a decline of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.07 Cr (net margin 0.3%) and EBITDA of ₹2.08 Cr (EBITDA margin 0.6%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 10% over five years.
The company has about 21 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Sai Sridhar Pharma. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012. Its 6 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 3 smaller; the largest is R S M Pharma Private Limited with revenue of ₹363.29 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ssppltd.com.
CIN History
Sai Sridhar Pharma has one previous CIN (Corporate Identification Number): U24232AP2007PTC055902. The current CIN is U24232TG2007PTC055902, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC055902 | Current |
| U24232AP2007PTC055902 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressPlot No : 5 First Floor Opp : Idpl Company Balanagar, Hyderabad, Telangana, India – 500037
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands
Sai Sridhar Pharma operates one associated brand: Sai Sridhar Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Operates as a pharmaceutical distributor supplying medical products. | ssppltd.com |
Business Activity
The main business activity of Sai Sridhar Pharma is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Financials of Sai Sridhar Pharma Private Limited
FY 2025 filings availableSai Sridhar Pharma Private Limited reported revenue of ₹349.28 Cr (down 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 21% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 10%. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | |
| Other Income | •••• | |
| Total Revenue | •••• | |
| Cost of Materials Consumed | •••• | |
| Employee Benefit Expense | •••• | |
| Finance Costs | •••• | |
| Depreciation and Amortisation | •••• | |
| Other Expenses | •••• | |
| Total Expenses | •••• | |
| EBITDA | ₹2.08 Cr | |
| Profit Before Tax | •••• | |
| Tax Expense | •••• | |
| Net Profit (PAT) | ₹1.07 Cr | |
| Balance Sheet | ||
| Share Capital | •••• | |
| Reserves and Surplus | •••• | |
| Net Worth (Total Equity) | •••• | |
| Long-term Borrowings | •••• | |
| Short-term Borrowings | •••• | |
| Trade Payables | •••• | |
| Total Liabilities | •••• | |
| Fixed Assets | •••• | |
| Investments | •••• | |
| Inventories | •••• | |
| Trade Receivables | •••• | |
| Cash and Bank Balance | •••• | |
| Total Assets | •••• | |
Financial Ratios
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 0.6% | |
| Net Profit Margin | 0.3% | |
| Return on Equity (ROE) | •••• | |
| Return on Capital Employed (ROCE) | •••• | |
| Return on Assets (ROA) | •••• | |
| Liquidity and Debt | ||
| Current Ratio | •••• | |
| Quick Ratio | •••• | |
| Debt-to-Equity Ratio | •••• | |
| Interest Coverage Ratio | •••• | |
| Efficiency and Growth | ||
| Asset Turnover | •••• | |
| Receivable Days | •••• | |
| Payable Days | •••• | |
| Inventory Days | •••• | |
| Revenue Growth | •••• | |
| Net Profit Growth | •••• | |
Paid data: the figures shown as dots, and every line for FY 2020-21 to FY 2023-24, are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sai Sridhar Pharma are in the company report.
: available in the company report
Board of Directors of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Udaya Lakshmi Tadepalli Also directs: Venkata Krishna Enterprises Private Limited | Additional Director | 23 May 2023 | 3 Years 4 Months | Current |
| Phani Srinivas Ramella Also directs: Deccan Medisales Private Limited, Venkata Krishna Enterprises Private Limited, Medplus Insurance Brokers Private Limited and 3 more | Director | 15 Mar 2010 | 16 Years 7 Months | Current |
| Paidiwar Srinivas Also directs: Dureleg Manufacturing Private Limited, Wynclark Pharmaceuticals Private Limited, Deccan Medisales Private Limited and 5 more | Director | 16 Oct 2017 | 9 Years 0 Months | Current |
| Satya Murali Krishna Kammila Also directs: Dureleg Manufacturing Private Limited, Wynclark Pharmaceuticals Private Limited, Deccan Medisales Private Limited and 5 more | Director | 29 Sep 2021 | 5 Years 0 Months | Current |
Peer Comparison
Sai Sridhar Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| R S M Pharma Private Limited | ₹363.29 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Bangalore, Karnataka, India |
| A M Pharmaceuticals (India) Private Limited | ₹359.11 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Thrissur, Kerala, India |
| Pangea Enterprises Private Limited | ₹353.08 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | New Delhi, Delhi, India |
| Sai Sridhar Pharma Private Limited this company | ₹349.28 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Hyderabad, Telangana, India |
| Abs Mercantiles Private Limited | ₹342.03 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Gurgaon, Haryana, India |
| Parkleton Private Limited | ₹339.03 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Delhi, India |
| Mankind Prime Labs Private Limited | ₹332.48 Cr (FY 2025) | •••• | •••• | 29.0% | •••• | New Delhi, Delhi, India |
Peers are the companies nearest to Sai Sridhar Pharma by revenue, above and below it, in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details
Sai Sridhar Pharma Private Limited is audited by G P H K and ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G P H K and ASSOCIATES | Locked | Locked | Locked |
: available in the company report
Ownership and Shareholding
: available in the company report
Charges & Borrowings
Sai Sridhar Pharma Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding
Sai Sridhar Pharma Private Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2012 | Funding round | ₹25 Lakh | Investors: Nova Sud Pharmaceuticals Private Limited |
| Sep 2009 | Secondary share transfer | Undisclosed | Buyer: Nova Sud Pharmaceuticals Private Limited Seller: 2 individuals |
: available in the company report
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance
Sai Sridhar Pharma Private Limited has a workforce of 21 employees as of Apr 08, 2024.
: available in the company report
Recent Activity
Sai Sridhar Pharma Private Limited has 8 board changes on record since 2010: 4 appointments and 4 cessations. The latest: Udaya Lakshmi Tadepalli was appointed as Additional Director on 23 May 2023.
Credit Ratings, Litigation & Regulatory Alerts
: available in the company report
MSME Payment Delays
: available in the company report
Subsidiaries & Group Companies
: available in the company report
GST Compliance
Sai Sridhar Pharma has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AALCS7507A2ZF | Telangana | Active | 01 Jul 2017 |
| 36AALCS7507A3ZE | Telangana | Active | 21 Mar 2024 |
| 37AALCS7507A1ZE | Andhra Pradesh | Active | 01 Jul 2017 |
: available in the company report
MCA Filings & Documents
: available in the company report
Frequently Asked Questions
Sai Sridhar Pharma is an active private limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 12 October 2007 (19+ years old) and is registered under CIN U24232TG2007PTC055902.
Sai Sridhar Pharma has 4 current directors:
- Udaya Lakshmi Tadepalli - Additional Director
- Phani Srinivas Ramella - Director
- Paidiwar Srinivas - Director
- Satya Murali Krishna Kammila - Director
The latest financial statements of Sai Sridhar Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 05 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Sai Sridhar Pharma is 36AALCS7507A2ZF, registered in Telangana. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 36AALCS7507A3ZE (Telangana), 37AALCS7507A1ZE (Andhra Pradesh).
The CIN (Corporate Identification Number) of Sai Sridhar Pharma is U24232TG2007PTC055902. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sai Sridhar Pharma was incorporated on 12 October 2007, making it 19+ years old. It is registered with the Registrar of Companies, Hyderabad.
Sai Sridhar Pharma has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012.
The peers of Sai Sridhar Pharma by revenue are R S M Pharma Private Limited, A M Pharmaceuticals (India) Private Limited, Pangea Enterprises Private Limited, Abs Mercantiles Private Limited, Parkleton Private Limited and 1 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Udaya Lakshmi Tadepalli was appointed as Additional Director on 23 May 2023. Satya Murali Krishna Kammila was appointed as Director on 29 Sep 2021. Paidiwar Srinivas ceased to be Additional Director on 30 Sep 2018. Sai Sridhar Pharma has 8 board changes on record in total.
Sai Sridhar Pharma can be reached through the website ssppltd.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of Sai Sridhar Pharma is at Plot No : 5 First Floor Opp : Idpl Company Balanagar, Hyderabad, Telangana, India – 500037.